On July 9, 2026, a new clinical trial involving pramlintide was listed on ClinicalTrials.gov. The trial, titled "Postprandial Regulation of Bone Perfusion in Healthy Individuals," carries the identifier NCT07679516.
The study status is listed as not yet recruiting, and the phase is marked as not applicable. No participants have been enrolled at this stage, and no outcomes or findings have been reported.
The registration indicates that the trial intends to examine bone perfusion in healthy individuals following meals, in relation to pramlintide. Further details, including eligibility criteria and recruitment timelines, are expected to be added as the study progresses toward its recruiting phase.
This update reflects only the current registration status of the trial and does not include any results, efficacy data, or safety information. As with all trials in early stages, specifics regarding methodology and objectives may evolve.
For more background on pramlintide, including its approved uses and regulatory status, readers can refer to the compound overview.